Know Cancer

forgot password

Use of Mouse Renal Adenocarcinoma Cell-containing Agarose-agarose Macrobeads in the Treatment of Patients With End-stage, Treatment-resistant Epithelial-derived Cancer

Phase 1
18 Years
65 Years
Open (Enrolling)
Intraabdominal Cancers (Various Types)

Thank you

Trial Information

Use of Mouse Renal Adenocarcinoma Cell-containing Agarose-agarose Macrobeads in the Treatment of Patients With End-stage, Treatment-resistant Epithelial-derived Cancer

Cancer in its various forms continues to be a major U.S. health problem, accounting for
550,000 deaths a year, as well as much disability and suffering. Treatment for cancer has
traditionally consisted of three modalities: surgery, radiation therapy, and chemotherapy.
Advances with all three modalities over the years have produced long-term remissions and/or
cures in certain types of cancer such as the leukemias, and prolonged survival for many
other patients. Much remains to be accomplished, however, especially with respect to the
treatment of solid tumors, including some of the most common cancers such as those of the
lung, colon, breast, ovary, prostate and kidney. New types of less toxic and debilitating
therapy are needed.

Among the therapeutic possibilities currently being explored, those that involve biological
control mechanisms seem both promising and attractive. Although it has long been thought
that cancer cells are not subject to the same regulatory growth control mechanisms that
function in normal cells, there is a substantial body of evidence that they can respond to
feedback signals telling them to slow or stop their growth. In addition, it has been
determined that a relatively small population of cells within a tumor (cancer "stem" or
progenitor cells) are responsible for continued tumor growth and that it is these cells that
must be controlled if biological anti-tumor therapy is to be effective.

The proposed cancer treatment being tested in this Phase 1 clinical trial is based on the
concept that tumor growth can be controlled by tumor mass or signals that indicate that such
mass is present. In this case, however, the induction of the growth-slowing signals is
brought about not by tumor mass, but by placing mouse kidney cancer cells in an agarose
matrix, which both selects for cancer progenitor cells and also causes them to produce and
release signals that inhibit the growth of freely growing cancer cells of the same or
different type in a laboratory dish or in a tumor-bearing animal or human (i.e. is also not
species-specific). This approach has proven both safe and effective in animal models and
veterinary patients, and it is now in the first stage of human testing. With Phase 1
completed, we are now implementing Phase 2 efficacy trials that for the present are focused
on colorectal cancer, pancreatic cancer, and prostate cancer. The Phase 1 trial remains
open to a range of epithelial-derived cancer.

Inclusion Criteria:

- End-stage, treatment resistant epithelial-derived cancer (carcinoma) arising
originally within the abdominal cavity with expected minimum six-month survival

Exclusion Criteria:

- Multiple intraabdominal metastases or carcinomatosis or other medical conditions
indicating that the procedure would be of too high a risk for the individual

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Evidence of toxicity by multiple parameters

Outcome Time Frame:

6 months

Safety Issue:


Principal Investigator

Barry H Smith, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

The Rogosin Institute


United States: Food and Drug Administration

Study ID:




Start Date:

January 2005

Completion Date:

December 2013

Related Keywords:

  • Intraabdominal Cancers (Various Types)
  • intraabdominal cancer (carcinomas)
  • agarose macrobeads
  • mouse kidney cancer cells
  • cancer cell growth inhibition



NewYork Presbyterian Weill Cornell Medical Center New York, New York  10021